Fly News Breaks for February 12, 2020
Feb 12, 2020 | 17:47 EDT
Goldman Sachs analyst Amit Hazan initiated coverage of Zimmer Biomet with a Buy rating and $177 price target. The analyst contends that the company can generate higher than modeled earnings results in FY21 due to a noticeable acceleration in Rosa robotic sales, "slightly improved" underlying orthopedic volumes, and incremental benefits from other new product launches such as cementless knees and Persona Revision knee system. Hazan believes that a higher premium for Zimmer Biomet is "attainable".
News For ZBH From the Last 2 Days
There are no results for your query ZBH